FDA warns GLP-1 drugs carry potential risk of rare eye condition
The U.S. Food and Drug Administration has required class-wide label updates for GLP-1 receptor agonists to warn of a potential risk of nonarteritic anterior ischemic optic neuropathy, a rare eye condition that can cause sudden vision loss. Drugs affected include Ozempic, Wegovy, Mounjaro and Zepbound. One FDA study found an increased risk against DPP-4 inhibitors but not SGLT-2 inhibitors, while a trial review recorded 15 probable cases. Manufacturers must add the warning to prescribing information. The agency has not established a causal link between the drugs and the condition.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The FDA requires class-wide label updates for GLP-1 receptor agonists warning of a potential risk of nonarteritic anterior ischemic optic neuropathy.
- ✓ Ozempic, Wegovy, Mounjaro and Zepbound are among the drugs covered by the new warning requirement.
- ✓ One FDA study found an increased risk of NAION against DPP-4 inhibitors but not against SGLT-2 inhibitors.
- ✓ A trial review recorded 15 probable cases of NAION associated with GLP-1 drugs.
What changed
The FDA moved from monitoring potential reports to requiring formal label changes across the entire GLP-1 drug class to include the NAION risk.
Live updates
-
FDA adds rare vision-loss warning to GLP-1 drugs including Ozempic and Zepbound
The U.S. Food and Drug Administration has required class-wide label updates for GLP-1 receptor agonists to warn of a potential risk of nonarteritic anterior ischemic optic neuropathy, a rare eye condition that can cause sudden vision loss. Drugs affected include Ozempic, Wegovy, Mounjaro and Zepbound. One FDA study found an increased risk against DPP-4 inhibitors but not SGLT-2 inhibitors, while a trial review recorded 15 probable cases. Manufacturers must add the warning to prescribing information. The agency has not established a causal link between the drugs and the condition.
Why it matters
GLP-1 drugs are widely prescribed for diabetes and weight loss, making any safety signal relevant to millions of patients. NAION involves damage to the optic nerve and can result in rapid, permanent vision loss in one or both eyes. The FDA action follows emerging reports and its own safety review, though regulators emphasize that the evidence does not yet prove the medications cause the condition. Patients currently using these drugs should consult their doctors before making any changes to their treatment.
What is confirmed
- The FDA requires class-wide label updates for GLP-1 receptor agonists warning of a potential risk of nonarteritic anterior ischemic optic neuropathy.
- Ozempic, Wegovy, Mounjaro and Zepbound are among the drugs covered by the new warning requirement.
- One FDA study found an increased risk of NAION against DPP-4 inhibitors but not against SGLT-2 inhibitors.
- A trial review recorded 15 probable cases of NAION associated with GLP-1 drugs.
- The FDA has not established that GLP-1 drugs cause NAION.
Still unconfirmed
- GLP-1 weight loss drugs can cause blindness.
What to watch next
- Manufacturer label submissions and updated prescribing information for Ozempic, Wegovy, Mounjaro and Zepbound
- Further FDA safety communications or post-market study results on GLP-1 drugs and NAION
- Clinical guidance for patients using GLP-1 drugs who experience sudden vision changes
confidence 50%Sources used for this update (21)
- arstechnica.com — Ars Technica - Serving the Technologist since 1998. News, reviews, and ...
- www.statnews.com — STAT — Reporting from the frontiers of health and medicine
- www.nbcnews.com — NBC News - Breaking Headlines and Video Reports on World, U.S....
- www.bostonglobe.com — MI5 chief says Iran is targeting military sites - The Boston Globe | New England news, weather and sports
- www.cnbcafrica.com — Oil falls after Trump declares ‘energy ceasefire’ between Russia and Ukraine | CNBC Africa
- www.thenationalnews.com — Arab Israelis wake to new political dawn after record election success
- www.medicaldaily.com — Salmonella Found in All Eight Oyster Samples From Virginia's Closed Little Wicomico River as Case Counts Diverge
- health.yahoo.com — Is It Mom Brain? Or Is It Actually ADHD?
- cashwalklabs.io — GM will switch to Nasdaq from the NYSE on Nov. 17
- CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
- STAT — FDA warns GLP-1 drugs carry potential risk of rare eye condition
- AP News — FDA adds rare vision-loss warning to popular GLP-1 drugs
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community